已收盤 07-18 16:00:00 美东时间
-0.680
-2.91%
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-18 21:30
Redburn Atlantic:下调Adobe(ADBE)评级至"卖出",目标价从420美元降至280美元
07-03 11:01
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $40 to $48.
07-02 18:47
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1141651881139785729.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital:维持SurgePays Inc(SURG)"买入"评级,目标价从8.75美元升至9美元</p> <p>• Ascendiant Capital:维持LiqTech Internatio
06-17 09:46
An announcement from Enliven Therapeutics ( ($ELVN) ) is now available. On June...
06-16 18:58
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced
06-13 18:16
Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achievingMMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved
06-13 18:06
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities:维持Mersana Therapeutics(MRSN)"买入"评级,目标价从9美元升至10美元</p> <p>• Guggenheim:维持Cabaletta Bio(CABA)"买入
05-17 08:44
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim:维持Cabaletta Bio(CABA)"买入"评级,目标价从23美元升至25美元</p> <p>• 瑞穗:维持Tectonic Therapeutic(TECX)"跑赢大市"评级,目标价从51美元
05-16 08:43
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.49) by 16.33 percent. This is a 5.56 percent decrease over losses of $(0.54) per share
05-15 04:35